Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC. (EXEL)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/17/2018 01/18/2018 01/19/2018 01/22/2018 01/23/2018 Date
27.49(c) 27.86(c) 28(c) 29.44(c) 30.4(c) Last
7 710 081 3 141 826 4 682 629 3 830 170 2 632 097 Volume
-7.28% +1.35% +0.50% +5.14% +3.26% Change
More quotes
Financials ($)
Sales 2017 453 M
EBIT 2017 166 M
Net income 2017 154 M
Finance 2017 246 M
Yield 2017 -
Sales 2018 615 M
EBIT 2018 244 M
Net income 2018 242 M
Finance 2018 482 M
Yield 2018 -
P/E ratio 2017 59,64
P/E ratio 2018 37,92
EV / Sales2017 18,7x
EV / Sales2018 13,4x
Capitalization 8 710 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company.It engages in the developing and commercializing small molecule therapies for the treatment of cancer.The company brands include comertriq and cobimetinib.Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
01/20 EXELIXIS : Announces Presentation of Updated Phase 1b Results for the Combinatio..
01/19 EXELIXIS : to Co-Host Financial Community Briefing to Discuss Data Presented at ..
01/19 EXELIXIS : and StemSynergy Enter into Exclusive Licensing Agreement for the Disc..
01/19 IPSEN : and Exelixis report positive data from hepatocellular carcinoma drug tri..
01/19 IPSEN : ends P3 trial on liver cancer early due to strong data
01/18 IPSEN : and Exelixis announce phase 3 trial results of cabozantinib demonstratin..
01/17 IPSEN : and Exelixis announce phase 3 trial results of cabozantinib demonstratin..
01/16 EXELIXIS : and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstratin..
01/09 EXELIXIS : to Co-Host Financial Community Briefing to Discuss Data Presented at ..
01/08 EXELIXIS : and StemSynergy Enter into Exclusive Licensing Agreement for the Disc..
More news
Sector news : Bio Therapeutic Drugs
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
EXELIXIS - 2013
A downturn could form
SELL
More Strategies
Latest Tweets
01/22Analysts’ Opinions Are Mixed on These Healthcare Stocks: Icon plc (NASDAQ: IC.. 
01/22$EXEL: Exelixis reports updated Phase 1b results for the combination of Cobim..
1
01/21Exelixis Announces Presentation of Updated Phase 1b Results for the Combinati.. 
01/20Exelixis Announces Presentation of Updated Phase 1b Results for the Combinati.. 
01/20Exelixis Announces Presentation of Updated Phase 1b Results for the Combinati.. 
More tweets
Qtime:86
News from SeekingAlpha
01/22 Exelixis & Ipsen Briefing For The Financial Community - Slideshow
01/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 18, 2018
01/18 YOUR DAILY PHARMA SCOOP : Juno Surges On Takeover Rumors, AEterna Zentaris Achie..
01/17 Investors unmoved by Exelixis' late-stage liver cancer data on cabozantinib; ..
01/17 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 16, 2018
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 34,0 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Executive VP, Chief Financial & Accounting Officer
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.-7.89%8 710
GILEAD SCIENCES13.04%105 754
VERTEX PHARMACEUTICALS5.41%39 951
REGENERON PHARMACEUTICALS-1.18%39 917
GENMAB13.75%11 762
BLUEBIRD BIO INC-1.21%8 064